CL
Cell Source, Inc.
CLCS · OTC
$0.40 -14.88% (-$0.07)
1M -41.18%
Market Cap $27.2M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$0.5
25.0% upside
Current Price
$0.4
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CLCS is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
-
N/A P/B N/A
P/FFO N/A
P/E N/A
Growth
-
N/A Book val. growth N/A
FCF growth N/A
EPS growth N/A
Profitability
-
N/A FCF margin N/A
Op. margin N/A
Gross margin N/A
Quality
57 /100
Average ROA 1,665.17%
Asset turnover 0.00x
ROIC 44.10%
Debt
0 /100
High Int. coverage -3.08x
Current ratio 0.02x
Net debt/EBITDA N/A
Stability
62 /100
Moderate EPS volatility 3.67%
Profitable years 0
Beta -157.98x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CLCS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Itamar Shimrat
Employees
1
Headquarters
New York City